Autologous and MHC class I-negative allogeneic tumor cells secreting IL-12 together cure disseminated A20 lymphoma

Blood

Volumn 101, Issue 2, 2003, Pages 568-575

  Curti, Antonio ^a   Parenza, Mariella ^a   Colombo, Mario P ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; GLYCOPROTEIN GP 70; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OX40; TUMOR VACCINE; UNCLASSIFIED DRUG;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOGRAFT; BYSTANDER EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DISSEMINATED CANCER; GENETIC TRANSDUCTION; IMMUNIZATION; IMMUNOGENICITY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VACCINE PRODUCTION;

EID: 0037438373     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0991     Document Type: Article

References (45)

1. Pardoll DM. Cancer vaccines. Nat Med. 1998;4:525-531.
2. Molldrem J, Lee P, Wang C, Felio K, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med. 2000;6:1018-1023.
3. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev. 1997;157:125-140.
4. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, et al. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood. 1998;91:222-230.
5. Van Baren N, Chambost H, Ferrant A, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukemia cells. Br J Haematol. 1998;102:1376-1379.
6. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286-293.
7. Molldrem J, Dermine S, Parker K, et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood. 1996;88:2450-2457.
8. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 1996;183:725-729.
9. Chen YT, Scanlan MJ, Sahin U, et al. Atesticular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997;94:1914-1918.
10. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colonystimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156.
11. Berard F, Blanco P, Davoust J, et al. Crosspriming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med. 2000;192:1535-1543.
12. Elder EM, Lotze MT, Whiteside TL. Successful culture and selection of cytokine gene-modified human dermal fibroblasts for the biologic therapy of patients with cancer. Hum Gene Ther. 1996;7: 479-487.
13. Kang WK, Park C, Yoon HL, et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther. 2001;12:671-684.
14. Borrello I, Sotomayor EM, Cooke S, Levitsky HI. A universal granulocyte-macrophage colonystimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines. Hum Gene Ther. 1999;10:1983-1991.
15. Nabel GI, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci U S A. 1996;93:15388-15393.
16. Colombo MP, Trinchieri G. Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2001;206:1-14.
17. Cavallo F, Signorelli P, Giovarelli M, et al. Anti-tumor efficacy of adenocarcinoma cells engineered to produce IL-12 or other cytokines compared with exogenous IL-12. J Natl Cancer Inst. 1997;89:1049-1058.
18. Dunussi-Joannopoulos K, Runyon K, Erickson J, et al. Vaccines with interleukin-12-transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood. 1999;94:4263-4273.
19. Nanni P, Nicoletti G, De Giovanni C, et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 2001;194:1195-1205.
20. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409-417.
21. De Giovanni C, Palmieri G, Nicoletti G, et al. Immunological and non-immunological influence of H-2Kb gene transfection on the metastatic ability of B16 melanoma cells. Int J Cancer. 1991;48:270-276.
22. Corbett TH, Griswold DP, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
23. Colombo MP, Vagliani M, Spreafico F, et al. The amount of IL-12 available at the tumor site is critical for tumor regression. Cancer Res. 1996;56:2531-2534.
24. De Giovanni C, Nicoletti G, Sensi M, et al. H-2Kb and H-2Db gene transfections in B16 melanoma differently affect non-immunological properties relevant to the metastatic process. Involvement of integrin molecules. Int J Cancer. 1994;59:269-274.
25. Huang AYC, Gulden PH, Woods AS, et al. The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A. 1996;93:9730-9735.
26. Glas R, Franksson L, Une C, et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK-cell mediated responses. J Exp Med. 2000;191:129-138.
27. Weinberg AD. OX40: targeted immunotherapy-implications for tempering autoimmunity and enhancing vaccines. Trends Immunol. 2002;23:102-109.
28. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: crosstalk relevant in innate anti-tumor immune response in vivo. Nat Med. 1999;5:405-411.
29. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med. 2002;195:327-333.
30. Tanaka F, Hashimoto W, Haruki O, Robbins PD, Lotze MT, Hideaki T. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin-18 using dendritic cells and natural killer cells. Cancer Res. 2000;60:4833-4844.
31. Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. In vivo priming of two distinct antitumor effector poulations: the role of MHC class I expression. J Exp Med. 1994;179:1215-1224.
32. Seung S, Urban JL, Schreiber H. A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med. 1993;178:933-940.
33. Huang AYC, Golumbek P, Mojgan A, Jaffee E, Pardoll D, Levitsky H. Role of bone marrowderived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
34. Heath WR, Carbone F. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol. 2001;19:47-64.
35. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumor localization, second signals and cross-priming in cytotoxic T-cell induction. Nature. 2001;411:1010-1012.
36. Parmiani G, Colombo MP, Melani C, Arienti F. Cytokine gene transduction in the immunotherapy of tumors. Adv Pharmacol. 1997;40:259-307.
37. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of all-ovectin-7, an HLA-B7/β2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 2001;7:2285-2291.
38. Nanni P, Rossi I, De Giovanni C, et al. Interleukin 12 gene therapy of MHC-negative murine melanoma metastases. Cancer Res. 1998;58:1225-1230.
39. Staveley-O'Carroll K, Sotomayor E, Montgomery J, et al. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci U S A. 1999;95:1178-1183.
40. Sotomayor EM, Borreilo I, Rattis F, et al. Cross-presentation of tumor antigens by bone-marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood. 2001;98:1070-1077.
41. + T cells in the antitumor immune response. J Exp Med. 1998;188:2357-2368.
42. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJM. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med. 1998;187:693-702.
43. Bansal-Pakala P, Jember AG, Croft M. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance. Nat Med. 2001;7:907-912.
44. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity. 2001;15:445-455.
45. Gramaglia I, Jember A, Pippig SD, Weinberg AD, Killeen N, Croft M. The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion. J Immunol. 2000;165:3043-3050.